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H
umans alter biodiversity in complex ways; sometimes, 
human impacts add biodiversity to ecosystems through spe-
cies introductions or restoration efforts, but in many cases 
they cause local biotic homogenization and loss of native biodi-
versity1–3. These changes to biodiversity have the potential to affect 
human and wildlife infectious diseases through a variety of mecha-
nisms, and understanding when, where and how this might happen 
could be important for predicting and mitigating disease outbreaks. 
Biodiversity–infectious disease interactions have roots as far back 
as the classic work of Charles Elton4 and have influenced the fields 
of integrated pest management of crops5. More recently, this topic 
has generated intense debate in the literature and media, and the 
question of its generality has become a subject of lively discussion 
in the discipline of infectious disease ecology6–19. Much published 
research supports the dilution effect hypothesis, which proposes 
that biodiversity can reduce the abundance of a particular para-
site species per host and thus reduce the risk of infectious disease 
caused by that parasite20–23. The dilution effect therefore predicts 
that biodiversity loss should increase infectious disease burden 
(with caveats noted below in ‘Points of agreement and contention’). 
Other studies support alternatives to the dilution effect, such as no 
relationship, a context-dependent relationship or an amplification 
effect6,11–14,24–26—defined by Keesing et  al.27 as the opposite of the 
dilution effect, or a positive relationship between biodiversity and 
risk of a particular infectious disease. Debate has also centred on 
whether managing species composition or biodiversity in general 
is more effective at reducing risk and whether human diseases are 
exceptions to general rules about biodiversity–infectious disease 
associations6,9,13,14,16,17,28–30. Hypotheses regarding biodiversity–dis-
ease relationships have potentially important public health, man-
agement and policy implications, because they imply that changes to 
biodiversity could increase or decrease disease, thus suggesting that 
biodiversity conservation could have unaccounted costs or benefits, 
respectively1,6,11–14,20,24–26,31. Despite this, there are few examples where 
biodiversity–disease relationships have been used to set policy or 
reduce disease burdens. We define biodiversity conservation as pre-
serving functioning ecosystems with predominantly native species 
and note that this is distinct from single-species conservation or 
restoration (see Supplementary Information for discussion of resto-
ration and biodiversity augmentation versus biodiversity conserva-
tion), which might also affect parasite transmission. The policy and 
management implications of this debate are real, given that there is 
a precedent for wildlife management to be used to control disease. 
For example, based on guidance from ecological models and theory, 
estate owners in Scotland have culled mountain hares in an attempt 
to reduce nematode infections in grouse32, and the British govern-
ment has culled European badgers in an attempt to limit the spread 
of Mycobacterium bovis, the causative agent of bovine tuberculosis33.
An improved understanding of biodiversity–disease relation-
ships could lead to considerable progress towards disease control. 
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As individuals with a diversity of perspectives on biodiversity–
disease relationships, we joined together to summarize the pri-
mary points of contention underlying the debate and to identify 
potential common ground, building upon several recent reviews 
of biodiversity–disease relationships13,15,20,31,34,35. We first describe 
the host–parasite systems that are most likely to be affected by 
changes to biodiversity. Throughout this Review, ‘biodiversity’ is 
generally used to refer to species richness, whereas ‘species com-
position’ accounts for the identity or relative frequencies of species 
in a community. Next, we summarize the points of disagreement 
in the biodiversity–disease literature. We then describe the state of 
the science by comparing the results of two recent synthetic sta-
tistical analyses of biodiversity–disease relationships. If biodiver-
sity management as a tool for disease control is considered in the 
broader context of other disease management options, we contend 
that it could have two primary benefits. First, it might prevent zoo-
notic and wildlife diseases from becoming problematic where they 
currently are not. Second, it might provide a means for managing 
existing diseases where no or few conventional interventions are 
available. If researchers can agree on this common ground, the 
resulting scientific and policy clarity could simultaneously improve 
ecosystem and human health.
How can biodiversity affect infectious disease?
Many pathogens might not interact with biodiversity (Fig. 1) or are 
well controlled in some settings by sanitation, drugs, pesticides or 
vaccines28. Other pathogens are likely to interact with biodiversity, 
including zoonotic diseases, which are caused by parasites that can 
be transmitted from animals to humans, and vector-borne diseases, 
which are transmitted by biting arthropods36–38. Hence, it is criti-
cal to identify the types of host–parasite systems most likely to be 
affected by biodiversity before asking whether positive, negative or 
neutral biodiversity–disease relationships predominate.
Biodiversity is unlikely to increase or decrease directly trans-
mitted, specialist parasites without free-living stages, intermediate 
hosts or vectors (Figs. 1 and 2). Examples include sexually trans-
mitted diseases of wild vertebrate and human hosts, such as simian 
and human immunodeficiency viruses, and the causative agents of 
human tuberculosis, measles, non-pandemic influenza and pneu-
monia, all of which have few interactions with species other than 
their host13,14,28 (Fig. 1). By contrast, parasites such as West Nile virus, 
which can infect humans and numerous species of birds29, the caus-
ative agent of Chagas disease, which can infect humans and various 
wild and domestic animals39,40, the bacterium causing leptospirosis, 
which is typically transmitted from rat excreta to humans41, and 
hantavirus, which can infect humans and numerous mammals42–44, 
might be more likely to be influenced by biodiversity31,45. The sensi-
tivity of these parasites to biodiversity also depends on the number 
and distribution of infectious stages and how they are transmitted 
(Fig. 1). For example, systems in which potential host contacts are 
limited—such as vectors that take a limited number of blood meals 
in their lifetime—are more likely to be affected by host and non-
host biodiversity than are parasites that spread billions of infective 
stages into the environment (but see ref. 46) (Fig. 1). Hence, multi-
host parasites, wildlife parasites, parasites with complex life cycles 
or free-living infectious stages, parasites with generalist vectors, and 
zoonotic parasites would be predicted to respond most readily to 
changes to biodiversity (that is, to be biodiversity-responsive para-
sites; Fig. 1). However, to the extent that biodiversity (1) regulates 
the density of susceptible wildlife hosts that might then pass directly 
transmitted parasites amongst themselves27 or (2) influences 
microbiota that protect against infectious diseases (for example, 
refs. 20,34,47), some of these expectations will need re-evaluation. 
Among these diversity-responsive parasites, negative effects of bio-
diversity on disease risk (that is, prevalence or per-capita parasite 
abundance) support the dilution effect, positive effects support the 
amplification effect, and unimodal relationships support both dilu-
tion and amplification under different circumstances. Finally, all of 
these patterns could be sensitive to the biodiversity and disease met-
rics used and the scale at which they are observed14,48,49.
To facilitate policy and management decision making, it is 
important to (1) identify which diseases are likely to respond to 
biodiversity, (2) understand the relationships between biodiversity 
and disease risk, (3) link biodiversity change to change in both dis-
ease burden (that is, loss of fitness due to disease) and metrics of 
disease risk, such as infection prevalence, (4) consider the ecologi-
cal and medical importance of a disease to a particular system or 
to humans, and (5) understand the trade-offs between biodiversity 
management and other land-use and public health options28,34 (see 
‘Research frontiers’ section). Indeed, different response variables, 
such as disease burden, prevalence, intensity and force of infection, 
might respond differently to biodiversity.
For example, pathogens that
specialize on humans and release
millions of infective stages, such as
measles, tuberculosis and pneumonia.
For example, sexually transmitted
diseases of humans, such as HIV.
For example, diarrheal diseases
that spread millions of infective
stages into the environment, such
as Giardia sp. and Escherichia coli.
For example, vector-borne diseases,
such as Lyme disease, West Nile virus
and Chagas disease; zoonotic
diseases, such as those caused by
hantaviruses, and parasites with
free living stages or complex life












































Fig. 1 | The frequency of interactions with biodiversity and transmission 
potential are likely to influence whether a parasite will be weakly or 
strongly affected by biodiversity. Transmission potential can be a product 
of releasing millions of infectious stages into the environment (high), or 
the number of blood meals a vector can take in its lifetime, or the number 
of sexual partners humans generally have in monogamous societies (low). 
When transmission potential is low, lost transmission events have a higher 
potential of reducing disease risk. However, to the extent that biodiversity 
regulates susceptible hosts27 and diverse microbiomes protect against 
infectious diseases (for example, refs. 20,34,47), some of these expectations 
will need re-evaluation. Credit: Measles photo, CDC/NIP/Barbara Rice; 
Giardia lamblia, CDC/Janice Haney Carr; HIV image, Matthew Cole / Alamy 
Stock Vector; tick photo, Scott Bauer, USDA Agricultural Research Service.
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Biologists generally agree that biodiversity affects some para-
sites and not others, so the measured effect of diversity on disease 
risk depends on whether all parasites or just diversity-responsive 
parasites are considered. This leaves two questions: (1) what frac-
tion of infectious diseases interact with biodiversity (and through 
what mechanisms)? and (2) for those diseases that interact with 
biodiversity, how often is the outcome positive, negative, neutral or 
nonlinear? By analogy, because we would not expect an antibacte-
rial compound to be effective against all pathogens, we would not 
ask how effective it is against pathogens other than bacteria. By this 
rationale, because we only expect biodiversity to interact with a 
subset of infectious diseases, when assessing whether biodiversity 
results in dilution or amplification, it is most relevant to consider 
only those pathogens that are likely to respond to biodiversity.
Points of agreement and contention
This section reviews the points of agreement and contention in bio-
diversity–infectious disease research.
What is the shape of the biodiversity–disease relationship? For 
diversity-responsive parasites, the relationship between diversity 
and disease risk might be nonlinear. No parasites can exist where 
host richness equals zero11,12,35,50,51. For this reason, most dilution 
effect research has focused on how biodiversity reductions in intact 
communities affect some metric of disease given that a parasite can 
complete its entire life cycle in that community7,23,27,31,52.
Given the likelihood that biodiversity–disease relationships 
will be nonlinear, it is crucial to know the relevant ranges over 
which to evaluate diversity and over which diversity is related to 
conservation action. If unimodal biodiversity–disease relation-
ships are often left-skewed or asymptotic, amplification effects 
should dominate, whereas if they are right-skewed, dilution should 
dominate14 (Fig. 3). Where the diversity of a community falls on 
these curves is also important, because if most communities fall 
in the right or left portions of unimodal diversity–disease curves, 
then dilution or amplification, respectively, will be most common, 
regardless of the direction of the skew (Fig. 3). We therefore must 
focus research on assessing the shape of diversity–disease risk 
relationships and identifying where systems generally fall along 
the x axis of diversity encompassed by these curves13,34,35,50 (see 
‘Research frontiers’ section).
What is the influence of habitat transformation or species com-
position on pathogen transmission, relative to the direct influ-
ence of biodiversity? Deforestation and urbanization can affect 
disease risk both directly and indirectly, via impacts on biodiversity, 
temperature, sanitation, access to health care, human population 
density, area of impervious surfaces, contact with biodiversity or 
other factors28,53. These multivariate relationships can make it dif-
ficult to disentangle the effects of biodiversity per se (see ref. 54 for a 
discussion of parasitism within the context of biodiversity–function 
relationships) on disease risk in changing landscapes9,28,35. Hence, it 
is crucial to control for these potentially confounding factors when 
testing for relationships between biodiversity and disease (for exam-
ple, ref. 28). If these demographic, economic and environmental fac-
tors have stronger impacts on disease burden than does changing 
biodiversity per se, then management of biodiversity could have a 
relatively small effect on disease.
In contrast to direct biodiversity–disease relationships, changing 
species composition, rather than diversity per se, can affect disease 
risk. This hypothesis states that the presence of certain host spe-
cies increases or decreases disease, and because many experimental 
studies manipulate species composition in conjunction with biodi-




















Fig. 2 | venn diagram depicting two primary disease management 
strategies, general proactive and targeted reactive approaches, and 
examples of each. Most disease management strategies are either 
proactive or reactive but some can be both. If dilution occurs more 
frequently than amplification, we postulate that the value of general 
biodiversity conservation might be to prevent: (1) multi-host, zoonotic and 
wildlife diseases from becoming problematic; (2) diseases where specific 
key hosts are hard to manage; and (3) diseases where little is known 
about their ecology, because too little is known to hone any intervention 
to specific species. In contrast, when the key hosts are manageable, 
interventions might be targeted to specific species or habitats that are 
known to amplify or dilute disease, which might make the intervention 
more effective than general biodiversity conservation. To the extent that 
biodiversity regulates the density of susceptible hosts that might then 
pass directly transmitted pathogens amongst themselves27 or influences 
microbiota that protect against infectious diseases (for example,  
refs. 20,34,47), some of these hypotheses will need re-evaluation. Although 
this figure is presented as a dichotomy, it does not imply that each  

























Fig. 3 | Hypothetical relationships between biodiversity and disease risk. 
The right-skewed distribution suggests that dilution might occur more 
frequently, but less intensely than amplification because the relationship 
is moderately negative over a greater portion of the biodiversity gradient 
than it is strongly positive. The left-skewed distribution suggests that 
amplification might occur more frequently but less intensely than dilution, 
because the relationship is moderately positive over a greater portion of the 
biodiversity gradient than it is strongly negative. An asymptotic distribution 
suggests that amplification becomes increasingly moderate with 
biodiversity. In addition to the shape of biodiversity–disease relationships, 
the frequency with which each biodiversity level occurs in the environment 
will also affect the likelihood and intensity of dilution and amplification. 
These hypothetical curves underscore the importance of documenting 
the shape of biodiversity–disease relationships, which has rarely been 
accomplished empirically.
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Species vary in their diluting and amplifying capacity based on 
their abundance, susceptibility and transmission potential, and thus 
certain species can disproportionately affect disease risk56. However, 
there is also support for biodiversity in general affecting disease, 
particularly when changes in diversity are substitutive—that is, add-
ing new species to a community reduces the abundance of existing 
species (for example, refs. 57–60). If species composition rather than 
diversity per se has a large effect on disease, then managing particu-
lar species might be more effective than managing overall biodiver-
sity. Some species, including many rodents, thrive in communities 
with few predatory species and thus low overall diversity: commu-
nities in which many zoonotic diseases can be amplified10. However, 
adding or sustaining top predator species in a community without 
increasing or maintaining biodiversity, respectively, could be diffi-
cult for predators that require an ample abundance and diversity 
of prey species. This observation that low-diversity communities 
contain a nested subset of their higher-diversity counterparts57 is 
an example of how diversity and species composition can be cor-
related20 (see ‘Research frontiers’ section). This correlation makes it 
challenging to disentangle composition from diversity in nature and 
to manage composition independent of biodiversity. Importantly, 
however, this correlation can make it easier to manage diseases than 
if diversity and composition were related to one another idiosyn-
cratically, because managing diversity will de facto result in man-
agement of composition20 (see ‘Research frontiers’ section).
What are the mechanisms underlying biodiversity–disease rela-
tionships? Some have suggested that the biodiversity–disease lit-
erature lacks evidence for convincing causal mechanisms for a 
relationship between biodiversity and disease (for example, refs. 61,62). 
However, decades of literature on the dilution effect hypothe-
sized explicit mechanisms23,50,52, and empirical support is growing 
for several of these. For example, communities with greater biodi-
versity might have greater densities of non-competent hosts, which 
can dilute disease by reducing encounters with vectors (for example, 
wasted bites)27, competing with competent hosts and reducing their 
densities44,49, or consuming free-living parasites or infected hosts 
(if the parasites are not trophically transmitted) (for example, 
refs. 58,59). When controlling for parasite exposure, traits of individual 
species may be predictive of whether they are likely to be a com-
petent (amplifying) or non-competent (diluting) host for a focal 
parasite, including phylogenetic relatedness to focal hosts36,63–65, 
life history and immunity or other defence strategies66–70, numeri-
cal abundance63,64,71, predilection to consume parasites relative to 
hosts58,59, and contact rates or connectedness within communities72. 
Alternatively, increasing biodiversity might theoretically increase 
the density of competent hosts, which amplify parasite burden by 
increasing rates of parasite or vector reproduction, by serving as 
long-lived reservoirs of infection, or by having high contact rates 
with other hosts73.
The extent to which mechanisms that are affected by species 
composition relate to biodiversity depends on community (dis)
assembly—how species are added to (or lost from) a commu-
nity—which can be affected by the previously mentioned species 
traits55,74,75. Community assembly can range from substitutive, in 
which individuals of a new species replace individuals of existing 
species in a community, to additive, in which adding new species 
adds more individuals to a community. Often, both substitutive and 
additive assembly occur within a community, because systems typi-
cally start assembling additively and shift to substitutive assembly 
as niches become more fully occupied and competition increases76.
Some community assembly mechanisms could produce ampli-
fication. For example, when community (dis)assembly is additive, 
amplification is expected because host densities increase as new 
host species are added to a community. When community (dis)
assembly is substitutive, amplification can occur when the addition 
of individuals of new, competent host species reduce the den-
sity of less competent host species27,50,52. Amplification or dilution 
can occur when competent hosts or non-competent hosts, respec-
tively, are added to or subtracted from communities via the sam-
pling effect (that is, more diverse communities are more likely to 
contain a host species that either strongly increases or decreases 
disease) (for example, ref. 77). Additionally, the overall burden of 
multiple diseases might increase through the cumulative effect of 
greater pathogen diversity78. If considering the cumulative effects 
of all pathogen species on a host population, host diversity could 
decrease the disease burden of individual pathogens (dilution) 
while simultaneously increasing the combined burden of all patho-
gens (see ‘Extrapolations beyond collected data’ section for further 
discussion and counter examples). Although this mechanism for 
an increase in disease is important for individual health, it would 
not meet the traditional definition of amplification27, which focuses 
on the prevalence or abundance of individual pathogen species in 
hosts, not the combined effects of all pathogens or an increase in 
pathogen richness.
Dilution should predominate when community disassembly is 
substitutive and competent hosts are abundant or are resilient to 
biodiversity loss. We focus on community disassembly because most 
of the literature on the dilution effect assumes biodiversity loss and 
thus disassembly. A commonly hypothesized mechanism for dilu-
tion assumes that: (1) parasites experience greater selection to infect 
abundant rather than rare hosts; (2) abundant hosts make consider-
able investments into reproduction, growth, and/or dispersal that 
might come at the expense of defences against parasites; (3) abun-
dant hosts are more likely to colonize and less likely to be extirpated 
from ecosystems; and (4) adding rare hosts reduces the abundance 
of common host species in high-diversity communities50,70. When 
these assumptions are met, a right-skewed biodiversity–disease 
relationship should result (Fig. 3), and abundant and widespread 
hosts might be amplifying hosts, while hosts with greater diluting 
potential would be added to communities as biodiversity increases, 
or would be lost from communities when they become fragmented 
or disturbed7,34,76,79. A combination of mesocosm experiments and 
field surveys demonstrates that the most abundant and widespread 
amphibian hosts are also the most competent hosts for a parasitic 
trematode species, supporting the notion that community disas-
sembly processes function in a manner consistent with the dilution 
effect for this parasite57. Similarly, community disassembly pro-
cesses support dilution effects documented for Lyme disease20,45,55,74. 
In a recent study, when plant communities were (dis)assembled 
randomly, dilution was not observed, but when they (dis)assembled 
naturally, biodiversity significantly reduced disease, again high-
lighting the potential importance of natural assembly processes80. 
Nevertheless, the generality of this dilution mechanism remains 
unclear, in part because the frequency with which natural com-
munities assemble and disassemble in a substitutive versus additive 
manner is not well characterized. Although we call for additional 
work, we emphasize that substantial progress has been made on 
mechanisms underlying biodiversity–disease relationships.
Extrapolations beyond collected data. Even when evidence sup-
ports a positive or negative biodiversity–disease relationship, there 
are often several links in the causal pathway between change in 
biodiversity and change in disease. Few studies have tracked all 
the links in this causal chain and links in the causal chain can act 
in opposite directions. For example, there are several links in the 
hypothesized causal chain connecting high vertebrate diversity to 
a high probability of zoonotic disease establishment and transmis-
sion in humans20, but not all of these pathways have strong scientific 
support10. There is considerable support for the argument that host 
diversity begets parasite diversity26,81–84. However, there is not con-
sistent support for the hypothesis that increasing parasite diversity 
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increases disease burden10. In fact, recent experimental work on 
wildlife and plants diseases57,78,85 showed that higher pathogen 
diversity can be associated with lower disease severity of individual 
pathogens in both plants85 and animals78. Ultimately, the impact of 
parasite species diversity on the health of hosts will depend on how 
the additional parasite species affect disease burden and severity 
(see ‘Research frontiers’ section).
Do biodiversity–disease relationships depend on scale? The 
dependence of dilution and amplification on spatial scale has been 
a common thread throughout the biodiversity–disease debate11,12,35. 
There are two main ways in which scale might influence the rela-
tionship between biodiversity and disease. First, Johnson et  al.34 
proposed that any relationship between biodiversity and infec-
tious disease should be strongest at local scales and weaken at 
larger scales. This prediction arises because species interactions 
affecting dilution and amplification occur at relatively small spa-
tial scales, whereas abiotic factors like climate tend to dominate as 
drivers of biological pattern at larger spatial scales. Cohen et  al.48 
found support for this hypothesis in the amphibian chytrid fun-
gus, West Nile virus and the bacterium that causes Lyme disease: 
at small spatial scales, host richness was a significant predictor of 
disease prevalence, whereas at larger spatial scales, the distribution 
of pathogens was more strongly influenced by climate and human 
population density48. Second, it is possible that the diluting capacity 
of a non-competent host might be most observable at small scales, 
where encounter reduction can occur, whereas the amplifying effect 
of a competent host might be most observable at larger temporal 
and spatial scales73. For example, for vector-transmitted diseases, 
removing a competent host can initially increase vector abundance 
on alternative hosts, suggesting a dilution effect, while over longer 
time and larger spatial scales, the removal of the competent host can 
ultimately cause decreases in the vector population73. Importantly, 
these results suggest that at least some of the variation in outcomes 
across biodiversity–disease studies could be a product of variation 
in the scales at which studies were conducted and at which mecha-
nisms operate (see ‘Synthesizing the evidence’ and ‘Research fron-
tiers’ sections). Indeed, biodiversity–disease studies have occurred 
from global to local scales6,81,86, while conservation actions and 
public health interventions generally occur at intermediate scales 
within countries6,28,86. In general, the most relevant studies are those 
conducted at temporal scales long enough to encompass pathogen 
life cycles and at spatial scales that are most relevant to both biodi-
versity–disease interactions and conservation, which are generally 
at the local to regional scales35.
Synthesizing the evidence
Two recent quantitative syntheses have examined the biodiver-
sity–disease relationship; each has different strengths, limitations 
and foci. These two syntheses attempted to assess the relative fre-
quencies of positive versus negative biodiversity–disease relation-
ships, whether such relationships are detectable for human diseases 
despite the influence of other forces on disease burden (for example, 
wealth and disease control efforts), and whether these relationships 
depend on scale17,28.
In a systematic meta-analysis of the published literature on bio-
diversity–disease studies, which included 202 effect sizes for 61 
parasite species, negative biodiversity–disease associations were 
common17 (see ref. 87 for similar findings among plant diseases). 
Negative diversity–disease associations were equally strong for zoo-
notic and wildlife diseases, and the meta-analysis did not reveal any 
significant context dependencies17, nor evidence of publication bias 
for zoonotic diseases18, though it is possible that null and ampli-
fication effects are underrepresented in the literature (that is, sys-
tem selection rather than publication bias) (Table 1). Additionally, 
although Civitello et al.17 did not explicitly quantify the scale of the 
studies in their meta-analysis, there were no significant differences 
in effect sizes between smaller-scale experimental and larger-scale 
correlative field studies, indicating that, within the range of scales at 
which the studies were conducted, scale was unlikely to affect the 
nature or strength of dilution effects17,18. These results suggest that, 
among the diseases for which relationships with biodiversity have 
been tested, a negative association (1) is frequently reported for 
wildlife and human diseases, (2) is robust across ecological contexts, 
and (3) is consistent across the spatial scales studied and between 
experimental and observational studies. However, many important 
human parasites have not been studied under these conditions and 
therefore could not be included in this meta-analysis, and many of 
the studies in the meta-analysis quantified infection prevalence or 
parasite abundance rather than disease burden (Table 1). Finally, in 
a meta-analytic framework, it is difficult to separate effects of spe-
cies composition (for example, sampling effects) from effects of bio-
diversity per se, although the meta-analysis included several studies 
that did separate these effects.
A second synthesis tested for associations between environmen-
tal, demographic, economic and social factors and disease burden 
for the 24 most important human infectious diseases tracked by the 
World Health Organization, of which 11 were potentially affected 
by biodiversity28. To do so, Wood et al.28 conducted a global analysis 
investigating across-country associations between disease burden 
(disability adjusted life years; DALYs) and biodiversity (country-
level bird and mammal species densities), while controlling for 
other potential drivers of disease burden, such as wealth, foresta-
tion and urbanization. All vector-borne or zoonotic diseases (that 
Table 1 | Characteristics that differ between the Civitello et al. 
and Wood et al. studies
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relevant diversity.
Includes diversity that 
is of questionable 
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scale with some 
spatiotemporal scales 
smaller than what is 
relevant in nature.
Medium scale. Largest scale.
Could have system 
selection bias.
No system selection 
bias.
No system selection 
bias.
Dilution Ambiguous Amplification
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is, biodiversity-responsive) examined in this study were positively 
associated with biodiversity at the across-country scale, though only 
five of the associations were statistically significant. By contrast, 
when considering changes in biodiversity and disease burden over 
time within each country, coefficients for seven diseases were nega-
tive (one significantly), and four were positive (one significantly). 
Thus, biodiversity effects were less positive at the within-country 
scale, relative to comparisons among countries28. Because the study 
is global, it relies on country-scale estimates of biodiversity, which 
include species not directly relevant to each disease (for example, 
total bird diversity in disease systems for which only mammals can 
become infected) (Table 1). Additionally, the spatial scale of analysis 
(intermediate-size countries) is larger than the scale at which spe-
cies interactions occur, but is a scale at which some policy decisions 
are made.
How can two synthetic analyses published two years apart come 
to such divergent conclusions? We hypothesize that the discrepan-
cies arise in part from differences in the spatial scales and meth-
ods of the studies (Table 1). Civitello et al.17 used published studies 
that experimentally investigated diversity–disease associations at 
logistically feasible scales that were substantially smaller than the 
within- and across-country spatial extents and grains included in 
Wood et al.28 (see Source Data Fig. 4). In fact, the median replicate 
size for studies on zoonotic parasites in Civitello et al.17, as com-
piled by Halliday and Rohr88 (for studies with ≥3 biodiversity levels 
and rounding all replicate sizes to the nearest order of magnitude), 
was 1.5 km2, whereas the median replicate size for the analyses in 
Wood et  al.28 was 321,489 km2. As discussed above, the associa-
tion between biodiversity and chytrid, West Nile, and Lyme disease 
declined with spatial scale in multiple regression analyses48, con-
sistent with the notion that mechanisms for dilution might operate 
at smaller scales than mechanisms for amplification. Clearly, the 
role of spatial scale in affecting the net effect of diversity on disease 
requires more attention.
We re-analysed data from Wood et al.28 to ask whether effect sizes 
in a single country through time differed from effect sizes across 
countries at a given time. Any disease designated as biodiversity-
responsive by Wood et al.28 was considered biodiversity-responsive 
for this re-analysis. We conducted a general mixed-effects linear 
model in which we treated as the response variable their 11 pairs 
of regression coefficients (one for the across-space comparison and 
one for the across-time comparison) for the effect of biodiversity 
on human disease burden of biodiversity-responsive diseases, with 
time versus space as the predictors, and the disease identity as a 
random effect (coefficients taken from the full model; see Fig. 1 of 
ref. 28). The positive coefficient between biodiversity and disease 
decreased significantly when transitioning from the across-country 
global comparison to the within-country, across-time compari-
son (F1,10 = 13.59, P = 0.0042, Fig. 4), from significantly positive 
at the cross-country global scale to non-significant at the within-
country scale over time. This re-analysis of the Wood et al.28 study 
suggests that when spatial scale is reduced from across to within 
countries (by considering a single country over time), biodiver-
sity–disease relationships become less positive (Fig. 4). However, 
numerous other important factors differ between the Wood et al.28 
and Civitello et al.17 studies (Table 1). For example, most studies in 
Civitello et al.17 assessed parasite prevalence or abundance, whereas 
Wood et al.28 analysed DALYs, which represent the burden of infec-
tion rather than parasite presence or abundance. Thus, for several 
reasons, we cannot definitively attribute differences in effect size 
and magnitude to differences in scale (Table 1).
It is important that we determine whether the relationship 
between biodiversity and disease does vary with spatial scale and, 
if so, that we identify the mechanisms that drive this relationship. 
Another key research frontier is evaluating the scale at which diver-
sity can be feasibly managed to reduce the burden of disease. When 
diversity at the scale of nations or continents predicts disease pat-
terns, information on the diversity–disease association seems most 
useful in assessing general risk at large scales. Biogeographic pat-
terns of diversity, however, are rarely if ever amenable to direct man-
agement for disease reduction. When diversity at local and regional 
scales predicts disease patterns, management of diversity will some-





























Fig. 4 | Hedges’ g effect sizes. Effect sizes are shown for the association 
between biodiversity and zoonotic parasites (plus typhoid, because Wood 
et al.28 suggest it is biodiversity-responsive) at the cross-country and 
within-country (through time) scales (median replicate size: 321,489 
km2; n = 11) from Wood et al.28 and various smaller-scale studies (median 
replicate size: 1.5 km2; n = 12) compiled by Civitello et al.17. Hedges’ g was 
provided by Civitello et al.17, whereas Wood et al.28 provided standardized 
regression coefficients. We converted the standardized regression 
coefficients to the Hedges’ g used in Civitello et al.17 by multiplying these 







properly account for the lack of independence among multiple effect sizes 
within studies and for the same diseases in Civitello et al.17, we calculated 
a mean effect size for each study weighting by the inverse of the variance, 
and then used inverse variance weighting on those study-wise means to 
obtain a weighted mean for each disease (see Source Data Fig. 4 for data 
used to generate this figure). In the Wood et al.28 study, the cross-country 
coefficient is significantly greater than zero (z = 5.82, P < 0.001), whereas 
the within-country (over time) coefficient is negative but not significantly 
different from zero (z = –1.20, P = 0.116). However, the relationship 
between these mean coefficients and scale is significantly positive (F1,10 = 
13.59, P = 0.0042), indicating that positive diversity–disease associations 
are more likely for among-country comparisons than for comparisons 
within a country, over time. Relative to Wood et al.28, smaller-scale studies 
compiled in Civitello et al.17 were more likely to find negative diversity–
disease associations. However, other factors also differ between the Wood 
et al.28 and Civitello et al.17 studies so we cannot confidently attribute all 
of this difference to the effect of scale. The midline of each boxplot is the 
median, the lower and upper limits of the box are first and third quartiles, 
respectively, the whiskers extend to 1.5 times the interquartile range, and 
the circles are extreme data points. Note that one extreme Hedges’ g value 
from Civitello et al.17 at –4.92 (Leptospira spp.) is not shown but was used to 
calculate the median, quartiles and whiskers of the boxplot.
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Towards common ground
Given that scientists struggle to predict which, when and where 
infectious diseases will become problematic, general preventa-
tive approaches that produce net reductions in disease could have 
considerable value (Fig. 2). Ecosystems regularly pose a threat 
of disease to humans and wildlife, but ecosystems vary in these 
threats. Thus, targeting conservation toward protecting ecosys-
tems that are not currently posing a major threat of problematic 
disease to humans or wildlife might prevent increases in dis-
ease (Fig. 2). In contrast, when the goal is to manage a specific 
disease whose ecology is reasonably well understood, it may be 
simpler and more effective to manage the particular species (vec-
tors or amplifying or diluting hosts) or habitats that are known 
to decrease or increase disease (for example, through vaccina-
tion, culling, predator supplementation and habitat manipula-
tion) than to conserve biodiversity in general (Fig. 2). However, 
management of particular species or habitats might only be effec-
tive against a focal pathogen. By contrast, preservation of intact, 
functioning ecosystems and finding sustainable, equitable inter-
ventions that discourage human incursions into those ecosystems 
(for example, for logging and bush-meat hunting), could reduce 
the risk of transmission of multiple pathogens, even if these inter-
ventions are not the single most efficient control method for indi-
vidual diseases. Thus, they could represent win–win scenarios for 
conservation and disease control.
When considering disease management strategies, the costs and 
benefits of each tactic and their alternatives must be evaluated thor-
oughly before implementation. For example, it is possible that the 
land needed for biodiversity conservation might have greater value 
to humans if it is used differently, such as for agriculture or devel-
opment, though it is also worth noting that sometimes the value 
arising from agriculture or development disproportionately accrues 
to outside commercial interests, while the health tolls are dispropor-
tionately borne by local communities89. Just as importantly, there are 
many reasons to conserve, restore and manage biodiversity that are 
unrelated to infectious disease, including other ecosystem services 
as well as ethical, aesthetic and cultural motivations. Additional 
health benefits from conservation can help make such actions more 
palatable when weighed against other land-use options.
Research frontiers
There are several outstanding questions in the biodiversity– 
disease literature that we have organized into five research frontiers: 
(1) pattern and process in biodiversity–disease relationships; (2) 
the shape of biodiversity–disease relationships; (3) metrics of dis-
ease and diversity; (4) context dependencies; and (5) public health 
and conservation.
Pattern and process in biodiversity–disease relationships. The 
foundational principles of disease ecology rest on a few well-studied 
disease agents, with many studies describing associations between 
biodiversity and disease rather than revealing the mechanisms that 
drive those patterns. We submit that the field needs to diversify, by 
both developing a broader understanding of biodiversity–disease 
patterns (that is, testing associations between biodiversity and dis-
ease beyond the disease agents that are already well studied) and 
narrowing in on the processes (that is, the mechanisms) that gener-
ate these patterns. A few macro-ecological investigations of biodi-
versity–disease pattern have already been conducted at the global 
scale (for example, refs. 26,28,86), but there is substantial promise in 
adopting this approach at regional or local spatial scales, which 
could reveal the conditions under which biodiversity–disease rela-
tionships are ecologically influential48. To discover what drives 
these ecologically influential relationships, experimental studies 
are needed to isolate mechanisms. For instance, most of the mecha-
nisms posited to explain the dilution effect involve substitutive 
community (dis)assembly, but it remains unclear how often com-
munity (dis)assembly is additive versus substitutive, how strongly 
this affects biodiversity–disease relationships, and whether the most 
competent hosts for infections are also the most robust to biodi-
versity loss under historical and current conditions20,31,34,75,90. The 
degree of correlation between species composition and biodiversity 
and the relative importance of stochastic and deterministic com-
munity assembly mechanisms are also not well established. The less 
deterministic community assembly is, the less effective biodiversity 
management might be as a tool for disease control. Finally, ecologi-
cal communities can also change stochastically through time (that 
is, ecological drift), which could cause temporal shifts in the roles of 
different dilution mechanisms at a given location.
The shape of biodiversity–disease relationships. Although there is 
consensus that biodiversity–disease relationships must be unimodal 
for dilution to occur, their propensity to be skewed to the left or 
right, and where they sit relative to the peak is unclear. For right-
skewed biodiversity–disease relationships, a larger proportion of 
the diversity axis would produce dilution, whereas for left-skewed 
biodiversity–disease relationships, a larger proportion of the diver-
sity axis would produce amplification. An even more challenging 
but equally important issue is determining how species richness val-
ues in nature are distributed along the diversity axis, and whether 
these tend to cluster on the portion of that axis where increasing 
biodiversity increases disease, or vice versa (Fig. 3).
Metrics of disease and diversity. Metrics of disease and diversity 
can vary widely across biodiversity–disease studies, but whether 
the choice of metric influences the study outcome is poorly under-
stood. For instance, because infections do not necessarily manifest 
in disease burden (that is, loss of host fitness), it is possible that 
parasite prevalence or intensity might be more sensitive to biodi-
versity than is disease burden. Like disease, biodiversity can also 
be measured or represented in many ways and this too has the 
potential to affect outcomes91. For instance, whether alpha, beta or 
gamma diversity affect disease differently is uncertain. Moreover, 
different subsets of biodiversity might have different effects on dis-
ease. For example, it remains unclear how parasite diversity affects 
the number of infections per host or disease78,85. Additionally, 
natural enemies of parasites (for example, predators58), symbionts 
of hosts (for example, host microbiomes47), and other non-host 
species can influence biodiversity–disease relationships, but the 
common mechanisms by which non-hosts affect infectious disease 
remain equivocal27,34,58.
Context dependencies. Some attribute disagreements over the bio-
diversity–disease relationship to an overemphasis on generality30; 
while there might be context dependencies for the biodiversity– 
disease relationship, we think it is worthwhile to seek the rules that 
govern when and where each form of biodiversity–disease relation-
ship might emerge. For example, there might be common traits of 
parasite species that are affected by biodiversity and common traits 
of host species that amplify or dilute disease13,14,58,59. If all host spe-
cies are unequal, then it raises the question: how strongly are biodi-
versity–disease relationships a product of the identity of particular 
host species (‘sampling effects’)1,34,51,58,92, an emergent property of 
biodiversity in general (‘complementarity effects’), or spurious cor-
relations driven by other factors?
Other ecological disciplines have identified relationships simi-
lar to the dilution effect. For instance, in the plant–herbivore lit-
erature, host plant diversity decreases herbivory, a phenomenon 
coined associational resistance93. The biodiversity–ecosystem func-
tioning literature has documented consistent positive relationships 
between biodiversity and ecosystem functions1, and the Red Queen 
hypothesis is based on the notion that genetic diversity within 
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a host species decreases infections per host65. What are the com-
monalities and differences among the dilution effect, associational 
resistance, biodiversity–ecosystem functioning and Red Queen 
hypotheses1,17,54,58,65,71,93, and are any differences a product of context 
dependencies?
An important potential context dependency for biodiversity–
disease relationships is spatial scale. How much of the variation in 
outcomes of biodiversity–disease studies arises from differences 
in the scale at which studies are conducted (spatial and temporal 
scales and the scope of the biodiversity gradient)12,34,48? There is a 
rich literature on the scale-dependent effects of ecological driv-
ers on biodiversity patterns91. Can it inform the biodiversity– 
disease discipline? More specifically, recent work shows that species 
composition often changes when it is measured at different spatial 
scales, and that measures of biodiversity are therefore often uncor-
related across scales94. Can this phenomenon, coupled with neutral 
sampling effects, cause different biodiversity–disease patterns to 
emerge at different scales? How important is the temporal scale of 
community assembly in revealing novel mechanisms linking host 
diversity to disease95?
Public health and conservation. Much of the controversy sur-
rounding the biodiversity–disease discipline has arisen from the 
suggestion that human health would benefit from biodiversity 
conservation. Not surprisingly, many questions and considerable 
work remain on the application of biodiversity management to pub-
lic health. For instance, some studies suggest mutual interference 
among co-infecting pathogens, such that an increase in parasite 
diversity generally decreases overall infections75. What is the general 
shape of the response surface for the relationships among disease 
and per-capita parasite diversity and abundance, and what are the 
public health trade-offs between more cases of one disease versus 
more different types of parasitic infections? How large is the unique 
effect of biodiversity compared to the unique effect of factors that 
commonly co-vary with biodiversity loss due to habitat conversion 
to more urban settings, such as increases in sanitation, access to 
health care and area of impervious surfaces? What are the trade-
offs of investing in conservation as a disease management approach 
versus other public health interventions?
Conclusions
We believe that most disease ecologists can agree on several ele-
ments of the biodiversity–disease debate. First, biodiversity should 
have a greater effect on multi-host, wildlife, vector-borne and zoo-
notic diseases, especially those parasites with complex life cycles 
and free-living stages, than on directly transmitted, host-specialist 
diseases. Second, the relationship between biodiversity and disease 
can be nonlinear, and identifying the shape of these relationships 
and where the diversity of a community falls on this continuum 
is critical for understanding when decreasing biodiversity will 
increase, decrease or have no effect on disease risk. Third, not all 
diseases are equal. Ebola is not the same as head lice, and from a 
conservation perspective, a disease causing widespread extirpations 
or extinctions is different from one that is not consistently caus-
ing wildlife declines. Fourth, biodiversity–disease relationships may 
be scale-dependent. Understanding the mechanisms that underlie 
this possible scale dependency could lead to insights into which 
management targets (biodiversity, particular species and human 
behaviour) and which scales of action are most effective for disease 
control. Outcomes with co-benefits for biodiversity and human 
health should be actively sought. Establishing consensus on these 
guiding principles will help to set a research and policy agenda for 
simultaneously improving ecosystem and human health.
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